9amHealth Secures $26M Series B for Virtual Chronic Care Expansion
May 14, 2026, 3:38 pm
Location: United States, California, San Francisco
Employees: 1-10
Founded date: 2019
9amHealth, a leader in AI-driven virtual specialty care, secured $26 million in Series B funding. This investment propels its expansion beyond cardiometabolic conditions. The company targets a broader spectrum of high-cost chronic diseases. Its platform offers comprehensive, scalable solutions for employers and health plans. 9amHealth leverages AI and specialized clinicians. The goal is to reduce healthcare spending and improve patient outcomes. This move solidifies its position in the evolving digital health landscape.
9amHealth recently announced a significant financial milestone. The company closed a $26 million Series B funding round. This capital infusion arrives at a pivotal moment. Virtual healthcare solutions are in high demand. Define Ventures led the round. Key investors included SemperVirens VC, Catalio Capital Management, and NewHealth Ventures. Previous backers, 7Wire Ventures and The Cigna Group Ventures, also support the firm. This funding fuels an ambitious expansion strategy.
The company plans to extend its AI-enabled virtual specialty care platform. Its current focus is cardiometabolic health. This includes conditions like obesity, diabetes, hypertension, and dyslipidemia. The expansion will target a wider range of chronic conditions. These ailments collectively represent a substantial burden. They account for up to 70% of employer pharmacy spending. Addressing these high-cost conditions is critical. It impacts both corporate budgets and employee well-being.
Founded in 2021, 9amHealth built a robust care model. It partners with enterprise employers, health plans, and pharmacy benefit managers. The platform delivers comprehensive medical care. This model integrates several components. Clinical protocols guide treatment. Laboratory testing provides essential data. Medication management ensures adherence. Ongoing virtual care services offer continuous support.
Central to 9amHealth’s approach is its technology. The platform combines specialized clinical care with AI-enabled workflows. This integration enhances scalability. It boosts operational efficiency. Personalized member experiences are also a hallmark. These features allow the company to manage complex chronic conditions effectively. Such conditions often require specialized medications. They demand recurring interventions and coordinated clinical care. These are significant drivers of employer healthcare costs.
The effectiveness of 9amHealth’s model is evident. The company reported impressive results. It generated over $50 million in projected medical and pharmacy savings. This was achieved across two Fortune 100 employers. Beyond cost savings, the platform improved member engagement. Clinical outcomes also saw significant improvements. This success demonstrates a clear return on investment for partners.
Members gain access to a team of experts. Endocrinologists provide specialized care for hormonal conditions. Obesity medicine specialists address weight-related health issues. Clinical pharmacists manage complex medication regimens. At-home laboratory testing simplifies diagnostics. Prescription medications are efficiently delivered. Lifestyle support services empower members. This holistic approach targets multiple facets of chronic disease management.
The strategic importance of this funding is clear. Lynne O’Keefe, Founder and Managing Partner at Define Ventures, joins the board. Her expertise will guide 9amHealth's growth. The investment validates the company's innovative approach. It underscores the market's need for scalable chronic care solutions. The rising demand for GLP-1 therapies further highlights this need. Effective management of these medications is paramount.
Chronic diseases pose a monumental challenge. They affect millions globally. Healthcare systems struggle with their complexity and cost. Traditional care models often fall short. They lack the continuous, integrated support many patients require. Virtual care bridges these gaps. It offers accessibility and convenience. It empowers patients in their own health journeys.
9amHealth is positioned at the forefront of this shift. Its platform offers a proactive solution. It moves beyond episodic care. It embraces a continuous engagement model. This reduces complications. It prevents costly hospitalizations. Employers seek innovative ways to control healthcare expenditures. They also aim to enhance employee health. 9amHealth provides a compelling answer.
The future of healthcare leans heavily on technology. Artificial intelligence holds immense promise. It can analyze vast datasets. It can personalize treatment plans. It can optimize care delivery. 9amHealth harnesses this potential. Its AI-enabled platform streamlines processes. It improves decision-making. It ensures consistent, high-quality care at scale. This technological edge is a key differentiator.
Expansion into new chronic conditions will broaden 9amHealth’s impact. The company has already built the necessary infrastructure. This includes clinical protocols. It encompasses care delivery systems. The technology platform is robust. These foundations enable efficient scaling. They support the management of more complex, higher-cost conditions. This preparedness is crucial for sustained growth.
The virtual specialty care market is expanding rapidly. Digital health solutions are no longer niche. They are becoming integral to healthcare delivery. 9amHealth's successful funding round reflects this trend. Investors recognize the value of scalable, evidence-based virtual care. The focus on employer-sponsored benefits is particularly strategic. Employers are powerful drivers of healthcare innovation. They seek solutions that directly impact their bottom line and workforce health.
9amHealth’s model offers a blueprint for the future. It demonstrates how technology and clinical expertise can merge. This combination delivers superior patient outcomes. It achieves significant cost reductions. The company is not just treating conditions. It is transforming how chronic care is delivered. This new funding ensures its continued leadership in the digital health revolution. The journey towards comprehensive, accessible chronic care management continues.
9amHealth recently announced a significant financial milestone. The company closed a $26 million Series B funding round. This capital infusion arrives at a pivotal moment. Virtual healthcare solutions are in high demand. Define Ventures led the round. Key investors included SemperVirens VC, Catalio Capital Management, and NewHealth Ventures. Previous backers, 7Wire Ventures and The Cigna Group Ventures, also support the firm. This funding fuels an ambitious expansion strategy.
The company plans to extend its AI-enabled virtual specialty care platform. Its current focus is cardiometabolic health. This includes conditions like obesity, diabetes, hypertension, and dyslipidemia. The expansion will target a wider range of chronic conditions. These ailments collectively represent a substantial burden. They account for up to 70% of employer pharmacy spending. Addressing these high-cost conditions is critical. It impacts both corporate budgets and employee well-being.
Founded in 2021, 9amHealth built a robust care model. It partners with enterprise employers, health plans, and pharmacy benefit managers. The platform delivers comprehensive medical care. This model integrates several components. Clinical protocols guide treatment. Laboratory testing provides essential data. Medication management ensures adherence. Ongoing virtual care services offer continuous support.
Central to 9amHealth’s approach is its technology. The platform combines specialized clinical care with AI-enabled workflows. This integration enhances scalability. It boosts operational efficiency. Personalized member experiences are also a hallmark. These features allow the company to manage complex chronic conditions effectively. Such conditions often require specialized medications. They demand recurring interventions and coordinated clinical care. These are significant drivers of employer healthcare costs.
The effectiveness of 9amHealth’s model is evident. The company reported impressive results. It generated over $50 million in projected medical and pharmacy savings. This was achieved across two Fortune 100 employers. Beyond cost savings, the platform improved member engagement. Clinical outcomes also saw significant improvements. This success demonstrates a clear return on investment for partners.
Members gain access to a team of experts. Endocrinologists provide specialized care for hormonal conditions. Obesity medicine specialists address weight-related health issues. Clinical pharmacists manage complex medication regimens. At-home laboratory testing simplifies diagnostics. Prescription medications are efficiently delivered. Lifestyle support services empower members. This holistic approach targets multiple facets of chronic disease management.
The strategic importance of this funding is clear. Lynne O’Keefe, Founder and Managing Partner at Define Ventures, joins the board. Her expertise will guide 9amHealth's growth. The investment validates the company's innovative approach. It underscores the market's need for scalable chronic care solutions. The rising demand for GLP-1 therapies further highlights this need. Effective management of these medications is paramount.
Chronic diseases pose a monumental challenge. They affect millions globally. Healthcare systems struggle with their complexity and cost. Traditional care models often fall short. They lack the continuous, integrated support many patients require. Virtual care bridges these gaps. It offers accessibility and convenience. It empowers patients in their own health journeys.
9amHealth is positioned at the forefront of this shift. Its platform offers a proactive solution. It moves beyond episodic care. It embraces a continuous engagement model. This reduces complications. It prevents costly hospitalizations. Employers seek innovative ways to control healthcare expenditures. They also aim to enhance employee health. 9amHealth provides a compelling answer.
The future of healthcare leans heavily on technology. Artificial intelligence holds immense promise. It can analyze vast datasets. It can personalize treatment plans. It can optimize care delivery. 9amHealth harnesses this potential. Its AI-enabled platform streamlines processes. It improves decision-making. It ensures consistent, high-quality care at scale. This technological edge is a key differentiator.
Expansion into new chronic conditions will broaden 9amHealth’s impact. The company has already built the necessary infrastructure. This includes clinical protocols. It encompasses care delivery systems. The technology platform is robust. These foundations enable efficient scaling. They support the management of more complex, higher-cost conditions. This preparedness is crucial for sustained growth.
The virtual specialty care market is expanding rapidly. Digital health solutions are no longer niche. They are becoming integral to healthcare delivery. 9amHealth's successful funding round reflects this trend. Investors recognize the value of scalable, evidence-based virtual care. The focus on employer-sponsored benefits is particularly strategic. Employers are powerful drivers of healthcare innovation. They seek solutions that directly impact their bottom line and workforce health.
9amHealth’s model offers a blueprint for the future. It demonstrates how technology and clinical expertise can merge. This combination delivers superior patient outcomes. It achieves significant cost reductions. The company is not just treating conditions. It is transforming how chronic care is delivered. This new funding ensures its continued leadership in the digital health revolution. The journey towards comprehensive, accessible chronic care management continues.